Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Zealand Pharma ASFRA:22Z +2.10%52 Cyclically Adjusted PS Ratio is 17.26 as of Jul. 30, 2026, which is 51% below its 10-year median of 35.06. GuruFocus rates FRA:22Z with a GF Score™ of 52/100. The stock has 3 warning signs investors should review. Among 538 Biotechnology companies, Zealand Pharma AS ranks worse than 78.62% on this metric.
The historical rank and industry rank for Zealand Pharma AS's Cyclically Adjusted PS Ratio or its related term are showing as below:
FRA:22Z'
s Cyclically Adjusted PS Ratio Range Over the Past 10 Years
Min: 13.32 Med: 35.06 Max: 179.43
Current: 17.21
During the past years, Zealand Pharma AS's highest Cyclically Adjusted PS Ratio was 179.43. The lowest was 13.32. And the median was 35.06.
FRA:22Z's Cyclically Adjusted PS Ratio is ranked worse than 78.62% of 538
companies
in the Biotechnology industry
Industry Median: 5.55
vs FRA:22Z: 17.21
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.
Zealand Pharma AS's adjusted revenue per share data for the three months ended in Mar. 2026 was €0.064. Add all the adjusted revenue per share for the past 10 years together and divide 10 will get our Cyclically Adjusted Revenue per Share, which is €2.34 for the trailing ten years ended in Mar. 2026.
Shiller PE for Stocks: The True Measure of Stock Valuation
Zealand Pharma AS (FRA:22Z) Cyclically Adjusted PS Ratio Explanation
Compared with the regular PS Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PS Ratio smoothed out the fluctuations of revenue during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Cyclically Adjusted PS Ratio should give similar results to regular PS Ratio.
Zealand Pharma AS Cyclically Adjusted PS Ratio Related Terms
Zealand Pharma AS Cyclically Adjusted PS Ratio Historical Data
* Premium members only.
The historical data trend for Zealand Pharma AS's Cyclically Adjusted PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Zealand Pharma AS Cyclically Adjusted PS Ratio Chart
FRA:22Z vs VRTX, REGN, RVMD: Cyclically Adjusted PS Ratio Comparison
For the Biotechnology subindustry, Zealand Pharma AS's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Zealand Pharma AS Cyclically Adjusted PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Zealand Pharma AS's Cyclically Adjusted PS Ratio distribution charts can be found below:
* The bar in red indicates where Zealand Pharma AS's Cyclically Adjusted PS Ratio falls into.
Zealand Pharma AS Cyclically Adjusted PS Ratio Calculation
Like the Shiller PE Ratio, the Cyclically Adjusted PS Ratio takes the Revenue per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/S calculation. Because it considers this 10-year average, it's often referred to as the CAPS Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio.
Zealand Pharma AS's Cyclically Adjusted PS Ratio for today is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
What does a Cyclically Adjusted PS Ratio of 17.26 mean?
Zealand Pharma AS (FRA:22Z) has a Cyclically Adjusted PS Ratio of 17.26 as of Jul. 30, 2026. Cyclically Adjusted PS Ratio is the ratio of share price to a company's inflation-adjusted revenue per share over a 10-year period. View historical data on Zealand Pharma AS and its competitors. This is 51% below median its historical median of 35.06. Over the past decade, Zealand Pharma AS's Cyclically Adjusted PS Ratio has ranged from 13.32 to 179.43. According to the industry distribution chart, Zealand Pharma AS ranks #423 out of 538 companies in the Biotechnology industry, placing it in the top 78.6%.
Is Zealand Pharma AS's Cyclically Adjusted PS Ratio too high?
Zealand Pharma AS's current Cyclically Adjusted PS Ratio of 17.26 is 51% below median its 10-year median of 35.06. Over the past 10 years, this metric has ranged from a low of 13.32 to a high of 179.43. The Biotechnology industry median Cyclically Adjusted PS Ratio is 5.55. Zealand Pharma AS's value of 17.26 is 211% above this industry median. Based on the distribution chart, Zealand Pharma AS ranks #423 out of 538 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Zealand Pharma AS has a GF Score™ of 52/100, reflecting its overall financial health beyond just this single metric.
How does Zealand Pharma AS's Cyclically Adjusted PS Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Zealand Pharma AS ranks #423 out of 538 companies for Cyclically Adjusted PS Ratio. This places Zealand Pharma AS in the lower half of its industry. The industry median Cyclically Adjusted PS Ratio is 5.55. Zealand Pharma AS's value of 17.26 is 211% above this benchmark. Historically, Zealand Pharma AS's own Cyclically Adjusted PS Ratio has ranged from 13.32 to 179.43 over the past decade. While the company's 10-year median is 35.06 vs. the industry median of 5.55, Zealand Pharma AS has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Cyclically Adjusted PS Ratio for a Biotechnology company?
The median Cyclically Adjusted PS Ratio among Biotechnology companies is 5.55, based on 538 companies in the industry. Companies in the top quartile (top 25%) have a Cyclically Adjusted PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, Cyclically Adjusted PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Zealand Pharma AS's current Cyclically Adjusted PS Ratio of 17.26 is 211% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Cyclically Adjusted PS Ratio mean?
A high Cyclically Adjusted PS Ratio can signal that a stock is expensive relative to its fundamentals. Cyclically Adjusted PS Ratio is the ratio of share price to a company's inflation-adjusted revenue per share over a 10-year period. View historical data on Zealand Pharma AS and its competitors. For the Biotechnology industry, the median Cyclically Adjusted PS Ratio is 5.55 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Zealand Pharma AS's current Cyclically Adjusted PS Ratio is 17.26, which is 51% below median its own 10-year median of 35.06. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Zealand Pharma AS stock overvalued right now?
Zealand Pharma AS (FRA:22Z) has a current Cyclically Adjusted PS Ratio of 17.26. The current Cyclically Adjusted PS Ratio is 17.26, which is 51% below median its 10-year median of 35.06 and 211% above the Biotechnology industry median of 5.55. Zealand Pharma AS's overall GF Score™ is 52/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Cyclically Adjusted PS Ratio calculated?
Cyclically Adjusted PS Ratio is calculated from a company's financial statements. For Zealand Pharma AS (FRA:22Z), the current Cyclically Adjusted PS Ratio is 17.26 as of Jul. 30, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Zealand Pharma AS is a biotechnology company. It is focused on the discovery, design, and development of peptide-based medicines. The company's product pipeline includes three product candidates in clinical development: glepaglutide, which is being developed to treat short bowel syndrome or SBS; dasiglucagon formulated for use in a dual-hormone artificial pancreas system for diabetes management; and dasiglucagon for use in the treatment of congenital hyperinsulinism. The company has out-licensed a peptide program to Boehringer Ingelheim that has been moved ahead into early clinical development: a once-weekly novel dual-acting GLP-1/glucagon agonist for the treatment of obesity and/or Type 2 diabetes.
52GF Score
Get the complete analysis for FRA:22Z
Cyclically Adjusted PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:22Z has been successfully added to your 
